{
    "clinical_study": {
        "@rank": "129534", 
        "arm_group": [
            {
                "arm_group_label": "Rikkunshito Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Rikkunshito", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to\n      placebo in Japanese subjects with Functional Dyspepsia."
        }, 
        "brief_title": "The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Functional Dyspepsia", 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Gastritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  -Patients diagnosed with FD according to the ROME III criteria i) Criteria fulfilled\n             for the last 3 months with symptom onset at least 6 months prior to obtaining\n             informed consent ii) Have not received upper endoscopy within the last 6 months prior\n             to enrollment and do not have evidence of structural/organic disease iii) Must have\n             one or more of the following symptoms:\n\n               1. Bothersome postprandial fullness\n\n               2. Early satiation\n\n               3. Epigastric pain\n\n               4. Epigastric burning\n\n          -  At least one of the FD-related symptoms on the Global Overall Symptom (GOS) scale\n             (bothersome postprandial fullness, early satiation, epigastric pain, epigastric\n             burning) is \u22654, whereas heartburn is \u22643.\n\n          -  Total score of depression-related symptoms on Hospital Anxiety and Depression Score\n             (HAD) is \u226410.\n\n          -  Type of visit: Outpatient\n\n          -  Provides voluntary informed consent after receiving adequate explanation and\n             demonstrates thorough understanding of the nature of the study.\n\n        Exclusion Criteria:\n\n          -  Confirmed ulcer (excluding scars) or malignant tumor in the upper GI\n\n          -  Suspected organic lesions in the hepato-biliary-pancreatic regions such as\n             cholelithiasis, hepatitis, pancreatitis\n\n          -  History of upper GI resection\n\n          -  Serious complications (liver, kidney, heart, or blood disease or metabolic disease)\n\n          -  Less than a year since testing positive for H. pylori or have undergone a successful\n             eradication therapy\n\n          -  Use of prohibited medications\n\n          -  Neuropsychiatric disorders\n\n          -  Use of or planned use of any investigational drugs\n\n          -  Unable to take drugs orally\n\n          -  History of allergic reactions to Kampo medicines\n\n          -  Pregnant or lactating women or those who are planning to conceive during the study\n             period\n\n          -  Deemed ineligible by principal investigator or sub-investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "460", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037776", 
            "org_study_id": "Tj43-p2-t1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rikkunshito", 
                "description": "- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks", 
                "intervention_name": "Rikkunshito", 
                "intervention_type": "Drug", 
                "other_name": "Tsumura Rikkunshito"
            }, 
            {
                "arm_group_label": "Rikkunshito Placebo", 
                "description": "- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks", 
                "intervention_name": "Rikkunshito placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rikkunshito", 
            "Double blind", 
            "Functional dyspepsia (FD)"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "tomy@med.osaka-cu.ac.jp", 
                "last_name": "Kazunari Tominaga, M.D., Ph. D.", 
                "phone": "+81-6-6645-3811"
            }, 
            "facility": {
                "address": {
                    "city": "Abeno-ku", 
                    "country": "Japan", 
                    "state": "Osaka", 
                    "zip": "545-8585"
                }, 
                "name": "Osaka City University Graduate School of Medicine"
            }, 
            "investigator": {
                "last_name": "Tetsuo Arakawa, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind Trial With Rikkunshito Versus Placebo on Efficacy and Safety in Patients With Functional Dyspepsia: Multi-center Study (DREAM Study)", 
        "overall_contact": {
            "email": "tomy@med.osaka-cu.ac.jp", 
            "last_name": "Kazunari Tominaga, M.D., Ph. D.", 
            "phone": "+81-6-6645-3811"
        }, 
        "overall_official": {
            "affiliation": "Osaka City University Graduate School of Medicine", 
            "last_name": "Tetsuo Arakawa", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Global assessment of overall treatment efficacy (OTE)", 
                "safety_issue": "No", 
                "time_frame": "At 4 week after treatment"
            }, 
            {
                "measure": "Global assessment of overall treatment efficacy (OTE)", 
                "safety_issue": "No", 
                "time_frame": "At 8 week after treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037776"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Osaka City University", 
            "investigator_full_name": "Kazunari Tominaga", 
            "investigator_title": "M.D., Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Global overall symptom (GOS)", 
            "safety_issue": "No", 
            "time_frame": "At 0, 4,8 week after treatment (including 14 days prior)"
        }, 
        "source": "Osaka City University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Osaka City University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}